



# Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide

*Johanna P. Cremers<sup>a</sup>, Marjolein Drent<sup>a,b</sup>, Aalt Bast<sup>b</sup>,  
Hidenobu Shigemitsu<sup>c,d</sup>, Robert P. Baughman<sup>e</sup>, Dominique Valeyre<sup>f,g</sup>,  
Nadera J. Sweiss<sup>h</sup>, and Tim L. Jansen<sup>i</sup>*

## Purpose of review

Although glucocorticosteroids are considered the first-line treatment in sarcoidosis, refractory cases require alternatives, such as methotrexate (MTX). The aim of this study was to develop, on behalf of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), multinational evidence-based recommendations for the use of MTX in sarcoidosis for routine clinical practice.

## Recent findings

A systematic literature search was conducted and combined with the opinions of sarcoidosis experts worldwide to formulate the recommendations. An online survey concerning 10 clinical questions was sent through the WASOG newsletter to sarcoidosis experts. Agreement about the recommendations amongst the world's leading sarcoidologists was evaluated. A total of 237 articles were identified, 43 of which were included. Randomized controlled trial evidence supporting the use of MTX in sarcoidosis was limited. Forty-five per cent (113 of 250) of the sarcoidosis experts contacted completed the survey (Europe 55%, North America 26% and Asia 12%). Ten recommendations were formulated concerning the indications for use, starting dose, folic acid, work-up, contraindications, monitoring, administration options in case of adverse gastrointestinal effects, hepatotoxicity, long-term safety and use during pregnancy and breast feeding.

## Summary

Ten multinational evidence-based recommendations for the use of MTX in sarcoidosis were developed, which are supported by the world's foremost sarcoidosis experts.

## Keywords

expert opinion, literature review, methotrexate, recommendations, sarcoidosis

<sup>a</sup>Department of Interstitial Lung Diseases, Gelderse Vallei Hospital, Ede, <sup>b</sup>Department of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands, <sup>c</sup>Division of Pulmonary and Critical Care Medicine, University of Nevada School of Medicine, Las Vegas, Nevada, <sup>d</sup>Division of Pulmonary and Critical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, <sup>e</sup>Interstitial Lung Disease and Sarcoidosis Clinic, Department of Internal Medicine, University of Cincinnati Medical Centre, Cincinnati, Ohio, USA, <sup>f</sup>Department of Pneumology, AP-HP, Avicenne University Hospital, <sup>g</sup>University Paris 13, Sorbonne Paris cité, Bobigny, France, <sup>h</sup>Sarcoidosis Translational Advanced Research Center (STAR), Department of Rheumatology, University of Illinois, Chicago, Illinois, USA and <sup>i</sup>Department of Rheumatology, University Medical Centre St Radboud, Nijmegen, The Netherlands

Correspondence to Professor M. Drent, MD, PhD, Department of Interstitial Lung Diseases, Gelderse Vallei Hospital, PO Box 18, 6720 AA Bennekom The Netherlands. Tel: +31 318 434819; fax: +31 842234007; e-mail: dretnm@zgvg.nl, www.ildcare.eu

**Curr Opin Pulm Med** 2013, 19:545–561

DOI:10.1097/MCP.0b013e3283642a7a

## KEY POINTS

- The majority of physicians (80%) consider methotrexate (MTX) as the first-choice second-line treatment in sarcoidosis; therefore, recommendations about the use in clinical practice are warranted.
- High-quality evidence supporting the use of MTX in sarcoidosis is, however, very limited. Most of the published data are observational case series.
- Ten multinational WASOG recommendations for the practical use of MTX in sarcoidosis were developed by integrating the evidence from both a systematic literature search and the expert opinions of sarcoidologists worldwide, and supported by the leading sarcoidosis experts.

## INTRODUCTION

Sarcoidosis is a multisystemic disease of unknown cause, characterized by inflammatory activity with noncaseating granulomas commonly developing in the lungs, but in other organ systems as well [1–3]. In severe sarcoidosis, the release of inflammatory mediators causes derangement of organ physiology and ultimately functional impairment and related symptoms. The disease stabilizes or improves in many cases over the first 2 years, but may worsen and become chronic in others [1]. As virtually any organ can be involved, patients may present with a wide variety of clinical signs and symptoms [1,2], and may first present to any one of a variety of organ specialists. As high-quality care and patients' expectations may not be covered by an individual specialist's expertise, recommendations for practical use can be expected to provide added value to optimize expertise in the field of sarcoidosis treatment.

Traditionally, glucocorticosteroids are considered the first-line treatment option in serious systemic sarcoidosis, but alternative treatment options have expanded tremendously [4,5]. Refractory cases, with steroid resistance or steroid-induced adverse effects, require alternatives to glucocorticosteroids [6,7], for which we propose to introduce the term disease-modifying antisaroid drugs (DMASDs). One option to be considered is that of potentiators of glucocorticosteroids, such as methotrexate (MTX) and azathioprine (AZA). Other DMASDs that may also play a role in controlling chronic granulomatous inflammation include leflunomide, mycophenolate mofetil, (hydroxy)-chloroquine, cyclosporine, cyclophosphamide and pentoxifylline [6–8,9<sup>\*\*\*</sup>]. If traditional cytotoxic DMASDs fail, new immunomodulating biological treatment modalities, such as tumour necrosis factor

alpha (TNF- $\alpha$ ) inhibitors, are available, providing elegant therapeutic options for refractory sarcoidosis patients [10,11]. In view of these promising results, a trend seems to be emerging amongst the healthcare providers towards a low threshold for switching from other second-line treatment options to biologicals. However, one of the drawbacks of using biologicals is their considerable costs [12<sup>\*</sup>]. It is important to optimize the utilization of less expensive, but effective disease-modifying therapeutics for granulomatous inflammation, in order to keep the healthcare system affordable and accessible to all.

MTX is often considered the first-choice DMASD used for patients with sarcoidosis, with 80% of physicians reporting MTX as their preferred second-line option [13<sup>\*\*</sup>,14]. MTX has proved to be a cornerstone therapeutic agent in a large group of immune-mediated diseases, such as rheumatoid arthritis (RA) and polymyositis [15,16]. The anti-inflammatory action of MTX can be attributed to the release of adenosine which elicits its effect via adenosine A<sub>2A</sub> receptors [17]. This action differs from the mode of action of steroids in inflammation [18<sup>\*</sup>]. Unfortunately, evidence for the use of MTX in sarcoidosis is limited, and evidence-based recommendations for its use in clinical practice are lacking.

On behalf of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), we aimed to develop practical recommendations for the use of MTX in sarcoidosis by integrating the evidence obtained through a systematic literature review and the opinions of sarcoidosis experts worldwide.

## METHODS

The new recommendations for the use of MTX in sarcoidosis on behalf of the WASOG were developed in four phases. First, we conducted a review of scientific evidence to create an evidence report on the use of MTX in sarcoidosis. The second phase comprised an evaluation of the experience with MTX amongst sarcoidosis experts around the world by means of an online web-based questionnaire. In the third phase, evidence obtained during phases 1 and 2 was combined to design 10 multinational recommendations. Finally, the recommendations were submitted to the world's leading sarcoidosis experts to assess whether they agreed with them and to evaluate how the recommendations would influence clinical practice.

## Systematic review of the literature

The literature search was carried out by five experienced sarcoidologists (M.D., H.S., R.P.B., D.V. and

N.J.S.) from three countries, one rheumatologist (T.L.J.), and one internal medicine resident and PhD student (J.P.C.). The computerized literature search for MTX relied predominantly on PubMed (articles from December 1968 to 28 March 2013). Reference lists of relevant review studies were checked to identify additional studies not found by the database search.

The terms 'sarcoidosis' and 'methotrexate' were entered as MeSH terms and free text. The search was limited to original research involving humans and published in English. Review articles were excluded from the systematic search, but were examined later to find other references. Data specifically relating to sarcoidosis were supplemented with the data obtained from important studies on other inflammatory diseases, with specific emphasis on rheumatic disorders, in view of the wide availability of evidence in this field.

### **Establishing expert opinion of sarcoidologists worldwide**

In view of the lack of sufficient high-quality studies on the use of MTX in sarcoidosis, the available evidence was supplemented with the expert opinion obtained from sarcoidologists worldwide. An online questionnaire was sent by e-mail through the WASOG newsletter to 250 experts around the world. The questionnaire addressed the following aspects: indications for use, starting dose, prescription of folic acid to reduce MTX toxicity, work-up prior to the start of MTX, contraindications, monitoring during use, administration options in case of adverse effects, hepatotoxicity, long-term safety, and use during pregnancy and breast feeding. Questions concerning the experts' clinical experience, specialty, the continent where they worked and the type of hospital were added as well. Experience with MTX in the treatment of sarcoidosis was assessed by the frequency of prescription: respondents prescribing MTX to more than 5 patients a year were defined as experienced and experts treating less than 5 patients a year with MTX as less experienced. Differences in response between experienced and less experienced specialists were examined using the Pearson's chi-squared test. When recapitulating the expert opinion based on the answers, the opinions of experienced sarcoidologists were given greater weight than those of less experienced respondents.

### **Establishing World Association of Sarcoidosis and Other Granulomatous Disorders recommendations**

The above-mentioned investigators (J.P.C., M.D., T.L.J., R.P.B., H.S., D.V. and N.J.S.) combined the

information gathered during phases 1 and 2 to formulate the 10 WASOG recommendations. Proposals were discussed via e-mail, phone and videoconference to finalize each of the recommendations.

The level of evidence for each recommendation was determined from the methodological quality of available studies in sarcoidosis, according to the levels of evidence of the Oxford Centre for Evidence-Based Medicine [19]. The grade of recommendation for each item was defined according to the Oxford Level of Evidence [19]. The authors focussed on formulating the recommendations in such a way so as to ensure their practical value to clinicians with less MTX prescription experience in sarcoidosis.

### **Evaluation of experts' agreement**

During the last phase of this study, the proposed set of recommendations was evaluated by 17 of the world's leading sarcoidologists, who answered three questions for every recommendation. Experts were asked to indicate whether they agreed with the recommendation; their level of agreement was measured on a 10-point visual analogue scale (1, no agreement to 10, full agreement) [20]; and the potential impact amongst the participants was assessed using three statements: 'This recommendation will change my practice'; 'I'm already working in accordance with this recommendation' and 'I will not change my practice with regard to this aspect'.

The total set of recommendations was also evaluated using these three questions, plus two additional queries: 'Do you think that these recommendations should be implemented in general clinical practice?' and 'Would you encourage your fellow physicians to implement these recommendations?'.

## **RESULTS**

The results of every phase were combined to develop the recommendations, which will be discussed subsequently.

### **Findings of the literature review**

The literature search identified 237 citations of potential interest. We screened each title and abstract for relevance resulting in the exclusion of 194 articles, as MTX had been used for non-sarcoidosis conditions (40 articles) or MTX had not been used as a pharmacological treatment option but in a different context (78 articles). Review articles were excluded as well (76 articles).

After this exclusion process, 43 articles were retrieved and considered further for full review. Checking the references in review articles yielded no additional original studies. Included were one randomized controlled trial (RCT), 10 case series involving more than 10 patients and 32 case reports involving fewer than 10 patients, examining the effectiveness of MTX in sarcoidosis. Study characteristics and results for each included article are summarized in appendix 1, <http://links.lww.com/COPM/A4>. Summarizing the available studies, it can be said that RCT evidence supporting the use of MTX in sarcoidosis was very limited, as only one RCT was available [21<sup>22</sup>] and most of the published data were observational case series [22<sup>23</sup>,24–63]. A Cochrane review for DMASDs in pulmonary sarcoidosis found no data on MTX available for meta-analysis [7].

Findings regarding expert opinion

A total of 113 of 250 (45%) experts completed the questionnaire. Characteristics of the respondents are presented in Table 1. The questionnaire was completed mainly by pulmonologists, rheumatologists and neurologists, working in countries all over the world (55% Europe, 26% North America and 12% Asia). Almost 60% of respondents could be classified as experienced with regard to MTX prescription for sarcoidosis. Eleven per cent of the respondents did not prescribe MTX at all in sarcoidosis patients, 70% of them quoting fear of toxicity as their reason for not doing so. Other reasons were ‘too little experience’ (42%) and ‘no indication for MTX as sarcoidosis cases were not severe enough’ (25%) (multiple options could be selected). The number of respondents experienced in MTX prescription for sarcoidosis was significantly higher in specialized sarcoidosis clinics and university hospitals than in general hospitals ( $P=0.001$ ) (data not shown).

Table 2 summarizes the results of the online questionnaire for each recommendation. Glucocorticosteroids monotherapy was by far the most commonly prescribed first-line treatment option, although MTX monotherapy was sometimes used

as first-line therapy. Experienced respondents were significantly more likely to prescribe steroid/MTX combination therapy as the first-choice treatment option than the less experienced respondents ( $P=0.003$ ). Furthermore, experienced respondents were significantly more likely to use the parenteral administration mode of MTX in cases complicated by gastrointestinal side-effects (including mucositis), whereas less experienced specialists were more likely to split the oral MTX dose as an alternative option ( $P=0.005$ ). Hepatic disease was significantly more often quoted as a contraindication for starting MTX by experienced participants ( $P=0.013$ ). No other significant differences between experienced and less experienced respondents were found. A small subgroup of sarcoidosis experts ( $n=14$ ) reported a 10% discontinuation rate of MTX, with the most important reported reasons for discontinuation including gastrointestinal (30% of cases), liver (27%) and haematological (17%) toxicity (data not shown). The results of the questionnaire were processed to formulate the recommendations.

Recommendations

The 10 key WASOG recommendations are listed in Table 3, with the corresponding level of evidence and grade of recommendation. The mean level of agreement for the total set of recommendations amongst the 17 leading sarcoidologists was 8.7 (range 8.0–10). The percentage of sarcoidologists who indicated that they would change their clinical practice in accordance with each of the recommendations is shown in Table 4. Twelve per cent of the sarcoidologists reported that the total set of recommendations would change their clinical practice; the other experts reported that they were already working according to the recommendations. All sarcoidologists were in favour of implementing these recommendations in general clinical practice and would encourage fellow physicians to use these recommendations.

Recommendation 1

*The indications for MTX in sarcoidosis consist of its use as a second-line treatment option in steroid-refractory*

Table 1. Summary of characteristics of sarcoidosis experts who participated in this study	
Number of respondents	113/250 (45.2%)
Pulmonologist/rheumatologist/neurologist/other	87.6/5.3/4.4/2.7%
Type of hospital: general/university/sarcoidosis clinic	21.2/56.6/22.1%
Continent: Europe/North America/Asia/other	54.9/25.7/12.4/7.1%
Working experience: 0–10/10–20/>20 years	24.8/31.0/44.2%
Average number of sarcoidosis patients treated with methotrexate: none/1–5/5–25/>25 a year	10.6/31.0/37.2/21.2%



**Table 2. Expert opinion amongst sarcoidologists, based on questionnaire answers, for each recommendation and level of methotrexate experience<sup>a</sup>**

	MTX prescription to 1–5 patients a year	MTX prescription to >5 patients a year	Total	P value
Number of respondents	35 (34.7%)	66 (65.3%)	101 (100%)	–
Recommendation 1				
First-choice treatment option (often/sometimes/never in %)				
Steroid monotherapy	97.1/2.9/0%	81.8/16.7/1.5%	87.0/12.0/1.0%	0.098
MTX monotherapy	0/38.2/61.8%	1.5/57.6/40.9%	1.0/51.0/48.0%	0.123
Steroid/MTX combination therapy	0/61.8/38.2%	18.2/66.7/15.2%	12.0/65.0/23.0%	0.003 <sup>a</sup>
Recommendation 2				
Starting dosage of MTX				
0–5 mg weekly	4 (12.1%)	10 (15.4%)	14 (14.3%)	0.409
5–10 mg weekly	20 (60.6%)	34 (52.3%)	54 (55.1%)	
10–15 mg weekly	8 (24.2%)	21 (32.3%)	29 (29.6%)	
>15 mg weekly	1 (3.0%)	0 (0%)	1 (1.0%)	
Maintenance dosage of MTX				
0–5 mg weekly	2 (6.1%)	0 (0%)	2 (2.0%)	0.068
5–10 mg weekly	12 (36.4%)	14 (21.5%)	26 (26.5%)	
10–15 mg weekly	16 (48.5%)	42 (64.6%)	58 (59.2%)	
>15 mg weekly	3 (9.1%)	9 (13.8%)	12 (12.2%)	
Recommendation 3				
Mean folic acid dosage				
1 mg daily	7 (21.9%)	22 (33.8%)	29 (29.9%)	0.052
5 mg once weekly	19 (59.4%)	18 (27.7%)	27 (38.1%)	
5 mg twice weekly	2 (6.3%)	7 (10.8%)	9 (9.3%)	
5 mg thrice weekly	1 (3.1%)	6 (9.2%)	7 (7.2%)	
Depending on MTX dosage	3 (9.4%)	12 (18.5%)	15 (15.5%)	
Recommendation 4				
Work-up before start of MTX				
AST	30 (85.7%)	62 (93.9%)	92 (91.1%)	0.167
ALT	31 (88.6%)	63 (95.5%)	94 (93.1%)	0.195
ALP and bilirubin	25 (71.4%)	59 (89.4%)	84 (83.2%)	0.022 <sup>a</sup>
CBC	33 (94.3%)	65 (98.5%)	98 (97.0%)	0.237
Creatinine	27 (77.1%)	55 (83.3%)	82 (81.2%)	0.449
Recommendation 5				
Contraindications				
Renal disease	23 (65.7%)	48 (72.7%)	71 (70.3%)	0.463
Hepatic disease	28 (80.0%)	63 (95.5%)	91 (90.1%)	0.013 <sup>a</sup>
Pulmonary disease	13 (37.1%)	13 (19.7%)	26 (25.7%)	0.056
Leucocytopenia	28 (80.0%)	52 (78.8%)	80 (79.2%)	0.886
Thrombocytopenia	27 (77.1%)	45 (68.2%)	72 (71.3%)	0.344
Anaemia	16 (45.7%)	33 (50.0%)	49 (48.5%)	0.682
Alcohol/drugs use (current or past)	19 (54.3%)	34 (51.5%)	53 (52.5%)	0.791
Infection acute/chronic	28 (80.0%)	53 (80.3%)	81 (80.2%)	0.971
Contraindicating creatinine clearance				
Stage 2 (GFR 60–89)	2 (8.7%)	3 (6.3%)	5 (7.0%)	0.427
Stage 3 (GFR 30–59)	11 (47.8%)	19 (39.6%)	30 (42.3%)	
Stage 4–5 (GFR <29)	10 (43.5%)	26 (54.2%)	36 (50.7%)	

**Table 2 (Continued)**

	MTX prescription to 1–5 patients a year	MTX prescription to >5 patients a year	Total	P value
Contraindicating WBC level				
<2.0 × 10 <sup>9</sup> /l	23 (92.0%)	32 (72.7%)	55 (79.7%)	0.119
<1.5 × 10 <sup>9</sup> /l	1 (4.0%)	10 (22.7%)	11 (15.9%)	
<1.0 × 10 <sup>9</sup> /l	1 (4.0%)	2 (4.5%)	3 (4.3%)	
Contraindicating platelet count number				
<200 × 10 <sup>9</sup> /l	3 (12.0%)	5 (11.4%)	8 (11.6%)	0.802
<100 × 10 <sup>9</sup> /l	14 (56.0%)	28 (63.6%)	42 (60.9%)	
<50 × 10 <sup>9</sup> /l	8 (32.0%)	11 (25.0%)	19 (27.5%)	
Contraindicating anaemia level				
<6 mmol/l	8 (44.4%)	17 (45.9%)	25 (45.5%)	0.995
<5 mmol/l	7 (38.9%)	14 (37.8%)	21 (38.2%)	
<4 mmol/l	3 (16.7%)	6 (16.2%)	9 (16.4%)	
Recommendation 6				
Blood monitoring interval after start of MTX				
Once after 2–3 weeks	12 (38.7%)	21 (32.3%)	33 (34.4%)	0.672
Every 2–3 weeks	13 (41.9%)	24 (36.9%)	37 (38.5%)	
Every 1–1.5 months	5 (16.1%)	15 (23.1%)	20 (20.8%)	
Every 2–3 months	1 (3.2%)	5 (7.7%)	6 (6.3%)	
Blood monitoring interval after stable MTX dose				
Every month	13 (41.9%)	15 (23.1%)	28 (29.2%)	0.299
Every 2 months	6 (19.4%)	15 (23.1%)	21 (21.9%)	
Every 3 months	11 (35.5%)	32 (49.2%)	43 (44.8%)	
Every 6 months	1 (3.2%)	3 (4.6%)	4 (4.2%)	
Recommendation 7				
Alternative administration modes in case of MTX-induced gastrointestinal side-effects				
Parenteral administration	0 (0%)	13 (20.0%)	13 (13.5%)	0.005 <sup>a</sup>
Splitting oral dose	14 (45.2%)	11 (16.9%)	25 (26.0%)	
Both	8 (25.8%)	19 (29.2%)	27 (28.1%)	
None	9 (29.0%)	22 (33.8%)	31 (32.3%)	
Recommendation 8				
First action when LT >4× ULN				
Check for alcohol/NSAID	18/35 (51.4%)	29/66 (43.9%)	47/101 (46.5%)	0.473
Increase folic acid dosage	4/35 (11.4%)	6/66 (9.1%)	10/101 (9.9%)	0.708
Decrease MTX dosage	7/35 (20.0%)	20/66 (30.3%)	27/101 (26.7%)	0.266
Parenteral MTX	1/35 (2.9%)	1/66 (1.5%)	2/101 (2.0%)	0.645
Discontinue MTX	25/35 (71.4%)	49/66 (74.2%)	74/101 (73.3%)	0.761
Start UDCA/antioxidants	7/35 (20.0%)	5/66 (7.6%)	12/101 (11.9%)	0.066
Level of LT abnormalities requiring MTX discontinuation				
>2× ULN	9 (29.0%)	20 (30.8%)	29 (30.2%)	0.912
>3× ULN	15 (48.4%)	30 (46.2%)	45 (46.9%)	
>4× ULN	7 (22.6%)	14 (21.5%)	21 (21.9%)	
No discontinuation	0 (0%)	1 (1.5%)	1 (1.0%)	
Recommendation 9				
Long-term MTX use				
Unaltered continuation	19/31 (61.3%)	44/65 (67.7%)	63/96 (65.6%)	0.537
Discontinuation	12/31 (38.7%)	21/65 (32.3%)	33/96 (34.4%)	0.800
After 1 year	4/12 (33.3%)	5/21 (23.8%)	9/33 (27.3%)	

**Table 2 (Continued)**

	MTX prescription to 1–5 patients a year	MTX prescription to >5 patients a year	Total	P value
After 2 years	6/12 (50.0%)	11/21 (52.4%)	17/33 (51.5%)	
After >2 years	2/12 (16.7%)	5/21 (23.8%)	7/33 (21.2%)	
<b>Recommendation 10</b>				
Establishing pregnancy wish				
In women	29/31 (93.5%)	64/65 (98.5%)	93/96 (96.9%)	0.196
In men	18/31 (58.1%)	46/65 (70.8%)	64/96 (66.7%)	0.217
Discontinuation of MTX if pregnancy wish				
In women	29/31 (93.5%)	64/65 (98.5%)	93/96 (96.9%)	0.196
In men	22/31 (71.0%)	45/65 (69.2%)	67/96 (69.8%)	0.862

<sup>a</sup>Values are expressed as frequencies and percentages, and were tested with Pearson's chi-squared test;  $P < 0.05$ , significant difference between the experienced and less experienced respondents.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; GFR, glomerular filtration rate expressed as ml/min and normalized to an average surface area (size) of 1.73 m<sup>2</sup>; LT, liver tests; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; WBC, white blood cell.

cases, in the presence of steroid-associated adverse effects or as a steroid-sparing agent; or as a first-line treatment option as a MTX/steroid combination therapy or monotherapy in exceptional situations.

The evidence to support MTX as a steroid-sparing agent or alternative agent is scarce. One small ( $n=24$ ) but high-quality RCT showed that sarcoidosis patients without previous treatment who took MTX 10 mg weekly required significantly lower doses of glucocorticosteroids than patients taking placebo, after 12 months of treatment [median 8.3 mg daily (0.83–21.7) and 16 mg daily, respectively,  $P < 0.001$ ]; at 6 months, there was no significant difference between the groups [21<sup>■</sup>]. A recent retrospective cohort study comparing the DMASDs MTX and AZA in sarcoidosis showed a significant steroid-sparing potency, without a difference between the two groups [22<sup>■</sup>]. The steroid-sparing potency of MTX was also found in several case series [24,26,28,46,51,52,54,56,57,63]. Moreover, MTX has been proven effective and is recommended as a steroid-sparing agent in other inflammatory diseases, such as RA, giant-cell arteritis and polymyalgia rheumatica, and can also be considered in systemic lupus erythematosus or (juvenile) dermatomyositis [64<sup>■</sup>].

Several case series are available for pulmonary and extrapulmonary sarcoidosis, and showed a 60–80% response to MTX in steroid-refractory cases or in the presence of steroid-associated adverse effects [22<sup>■</sup>,23<sup>■</sup>,24–63]. MTX appeared to take 6 months to be effective. The previously described retrospective cohort study comparing MTX and AZA found a positive effect of MTX on lung function [22<sup>■</sup>]. Lower and Baughman [28] showed that 33 of

50 patients using MTX for 2 years saw their vital capacity improve by more than 15% or showed improvement in other organs. Vucinic [24] showed an improvement in forced expiratory volume in 1 s (FEV1) in 80% and in diffusing capacity for carbon monoxide (DLCO) in 65% of 91 sarcoidosis patients using MTX for 6 months. The only available RCT did not find a significant effect of MTX on lung function (vital capacity), symptoms or adverse events compared to placebo. However, the study may not have been adequately powered to demonstrate the true effect of MTX because of the small number of patients enrolled in the study [21<sup>■</sup>].

Some exceptional manifestations of sarcoidosis might respond better to nonsteroidal drugs. In these cases, MTX/steroid combination or MTX monotherapy can be considered as the first-line treatment option. However, this recommendation is mostly based on expert opinion rather than evidence. Experienced sarcoidologists in particular seemed to consider MTX as a first-choice therapy in such cases (Table 2). For example, first-line systemic MTX therapy, whether or not combined with glucocorticosteroids, has been reported as beneficial in uveitis after topical steroid application failed [23<sup>■</sup>,26]. MTX has been proposed as a first-choice immunosuppressant in neurosarcoidosis [65]. An MTX/glucocorticosteroids combination has been reported to be beneficial as a first-line treatment option in neurosarcoidosis [27,36,40,46,61], as many neurosarcoidosis manifestations are usually chronic and MTX appears to show increased efficacy at lower levels of morbidity [27]. Another indication is cardiac involvement, in which a first-line MTX/glucocorticosteroids combination therapy should

**Table 3. Multinational recommendations for the use of methotrexate in sarcoidosis**

Recommendation		Level of evidence [19]	Grade of recommendation [19]	Agreement mean ( $\pm$ SD) <sup>a</sup>
1	The indications for MTX in sarcoidosis consist of its use as a second-line treatment option in steroid-refractory cases, in the presence of steroid-associated adverse effects or as a steroid-sparing agent; or as a first-line treatment option as a MTX/steroid combination therapy or monotherapy in exceptional situations.	2b	B	8.9 ( $\pm$ 1.1)
		4	C	
2	The recommended initial dosage of oral MTX is 5–15 mg weekly.	4	C	9.0 ( $\pm$ 1.6)
3	Prescription of folic acid with MTX therapy is recommended, at least 5 mg weekly or 1 mg daily.	5	B <sup>b</sup>	9.6 ( $\pm$ 1.1)
4	The preadministration work-up for patients starting MTX should include aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin, complete blood count (CBC), creatinine, and when indicated, serology for HIV, hepatitis B/C and IGRA test for <i>Mycobacterium tuberculosis</i> infection.	5	D	9.1 ( $\pm$ 1.1)
5	Before starting MTX, some contraindications should be considered: significant renal disease, significant hepatic disease other than sarcoidosis, bone marrow depression and acute or chronic infection.	5	D	9.3 ( $\pm$ 1.2)
6	When starting MTX or increasing the dose, ALT with or without AST, creatinine and CBC should be monitored every 3–6 weeks until a stable dose is reached, and every 1–3 months thereafter; after stabilization the monitoring interval can be extended to every 6 months.	5	D	8.9 ( $\pm$ 1.3)
7	In case of MTX-induced gastrointestinal side-effects, including mucositis, splitting the oral dose should be considered, provided the total MTX dose is ingested within a 12-h period. Parenteral administration or an alternative immunosuppressive drug should be considered in case of persistent intolerance.	5	D	8.3 ( $\pm$ 2.0)
8	Caution is warranted if there is a confirmed increase in ALT/AST. If there are no other causes, it should lead to either MTX dose reduction or withdrawal, liver biopsy to evaluate for MTX toxicity or additional folic acid supplementation; consider an alternative immunosuppressive drug after normalization.	4	C	9.0 ( $\pm$ 1.4)
9	Based on its acceptable safety profile, MTX is appropriate for long-term use.	5	C <sup>b</sup>	9.3 ( $\pm$ 1.1)
10	MTX should not be used by men or women for at least 3 months before planned pregnancy, and should not be used during pregnancy or breast feeding (absolute contraindication).	5	D	9.5 ( $\pm$ 0.9)

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; IGRA, interferon-gamma release assay; MTX, methotrexate.

<sup>a</sup>The level of agreement was measured on a 10-point visual analogue scale (1, no agreement; 10, full agreement).

<sup>b</sup>Upgraded level of recommendation based on evidence derived from rheumatoid arthritis studies.



**Table 4. Evaluation of recommendations, with the percentage of sarcoidologists who indicated that each of the recommendations would change their clinical practice or not**

Recommendation	The recommendation will change my practice (%)	Already working according to this recommendation (%)	I will not change my practice in this respect (%)
1. Indications for use	5.9	94.1	0
2. Starting dosage	0	88.2	11.8
3. Folic acid	11.8	88.2	0
4. Preadministration work-up	5.9	88.2	5.9
5. Contraindications	11.8	88.2	0
6. Monitoring	0	94.1	5.9
7. Adverse effects and administration	17.6	64.7	17.6
8. Hepatotoxicity	0	94.1	5.9
9. Long-term safety	0	100	0
10. Pregnancy	0	100	0

be considered to avoid aneurysm formation because of high doses of glucocorticosteroids [66]. Starting MTX with low-dosed glucocorticosteroids might also be beneficial for patients suffering from diabetes or overweight whose prednisone dose should be kept as low as possible, as the required cumulative glucocorticosteroids dose with MTX is several milligrams lower than without MTX [21<sup>¶</sup>].

## Recommendation 2

*The recommended initial dosage of oral MTX is 5–15 mg weekly.*

The single available RCT demonstrated that an initial oral MTX dosage of 10 mg weekly had steroid-sparing efficacy [21<sup>¶</sup>], whereas case series showing effectiveness of MTX used dosages of 5–20 mg weekly [22<sup>¶</sup>,23<sup>¶</sup>,24–63]. The safety profile of MTX in these cases was acceptable (see appendix 1, <http://links.lww.com/COPM/A4>). Most research experience has been in the initial dosage range of 10–15 mg weekly. Eighty-five per cent of sarcoidologists reported using starting dosages of 5–15 mg weekly (Table 2). A lower initial MTX dosage is advisable in case of suspected bone marrow involvement in the sarcoidosis process, as evidenced by cytopenia [67,68].

Studies comparing different MTX dosages in sarcoidosis are not available, and there is a need for future studies to compare higher and lower dosages of MTX to provide the best treatment effect with acceptable safety profile. Studies comparing different dose-escalation methods are not available for sarcoidosis either, but in RA the results of three RCTs directly comparing different dosages of oral MTX showed dose-dependent efficacy and toxicity [64<sup>¶</sup>,69–71]. The higher starting doses (12.5–25 mg weekly) were clearly more effective in RA patients

than the lower doses (5–15 mg weekly), but were accompanied by more adverse effects [69,70]. Rapid dose escalation by 5 mg monthly was associated not only with higher effectiveness, but also with more adverse events, in comparison with escalation of 5 mg every 3 months [71]. Table 2 shows that 86% of the sarcoidologists recommended a maintenance dosage of MTX for sarcoidosis of 5–15 mg weekly, but 12% reported that higher dosages of up to 20 mg weekly may be warranted in individual cases. As the treatment effect and safety profile for higher dosages of MTX in sarcoidosis have not been determined, increasing the dose of MTX for sarcoidosis beyond 20 mg weekly is probably not advisable without appropriate safety studies. Evidence regarding the best escalation method in sarcoidosis is not available, but in the case of insufficient response and an acceptable safety profile we recommend considering escalation after 8 weeks to 10–15 mg weekly with a maximum of 20 mg weekly in individual cases.

## Recommendation 3

*Prescription of folic acid with MTX therapy is recommended, at least 5 mg weekly or 1 mg daily.*

No studies on the prescription of folic acid with MTX therapy for sarcoidosis are available. A meta-analysis of 9 studies in RA, including 788 patients, suggested that folic acid supplementation reduces the gastrointestinal and liver toxicity of MTX, without reducing its efficacy [64<sup>¶</sup>,72]. High dosages of folic acid (>5 mg weekly) led to a significant reduction in gastrointestinal side-effects (odds ratio [OR] 0.42; 95% confidence interval [CI] 0.21–0.85) [73–76], whereas dosages of less than 5 mg weekly showed only a trend towards reducing gastrointestinal side-effects [74]. After further stratification, however, the protective effect of folic

acid on gastrointestinal toxicity proved only significant in the studies that used MTX at weekly doses of less than 10 mg [74,75]. The studies analysing hepatotoxicity showed a significant protective effect of 1 mg folic acid daily or 7 mg weekly (OR 0.17; 95% CI 0.09–0.32) [73,75,76]. The effect of folic acid supplementation on haematological adverse effects could not be accurately assessed because of a low incidence of events in the samples studied [77]. Almost 70% of the sarcoidologists recommended prescribing folic acid at 1 mg daily or 5 mg weekly, whereas 17% reported prescribing higher dosages.

At least 5 mg folic acid weekly is recommended for RA, taking into account the potential need for higher dosages if MTX is given in higher doses [64<sup>■</sup>]. Similar prophylaxis is recommended in sarcoidosis, as data on the prescription of folic acid or data supporting the need for higher dosages to provide adequate prophylaxis in sarcoidosis are not yet available.

#### Recommendation 4

*The preadministration work-up for patients starting MTX should include aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin, complete blood count (CBC), creatinine, and when indicated, serology for HIV, hepatitis B/C and interferon-gamma release assay (IGRA) test for Mycobacterium tuberculosis infection.*

The work-up information needed to decide whether to start a patient with sarcoidosis on MTX can be extrapolated from data on MTX-induced toxicity. Studies investigating the risk factors for severe toxicity in sarcoidosis are lacking, but data on RA suggested that an estimated creatinine clearance less than 79 ml/min increases the risk of severe pulmonary toxicity [64<sup>■</sup>,78]. Furthermore, lung abnormalities on radiograph, but not pulmonary function tests, proved predictive of MTX-induced pneumonitis [64<sup>■</sup>,79–81]. Exacerbation of hepatic disease was an additional risk in obesity, diabetes and viral/alcoholic hepatitis [64<sup>■</sup>,82–85].

Recommendations in Europe and the USA about the preadministration work-up for arthritis patients all suggest CBC, creatinine, AST, ALT with or without bilirubin and ALP [86<sup>■</sup>,87]. Hepatitis B/C serology, serology for HIV and chest radiographs have also been suggested as part of the pretreatment work-up [64<sup>■</sup>,87,88]. Table 2 shows that 83–99% of the sarcoidosis experts reported AST, ALT, ALP, bilirubin, CBC and creatinine to be part of their preadministration work-up (Table 2). A chest radiograph is usually available in sarcoidosis patients, as the lungs are commonly involved in

the sarcoidosis process [1,2]. An additional chest radiograph as part of the preadministration work-up does not offer added value, and we therefore do not recommend routine chest radiographs. Only in cases with suspected pulmonary infection, established during clinical evaluation before the start of MTX, is an additional chest radiograph recommended to determine a change in the features (based on expert opinion).

Sarcoidosis and tuberculosis (TB) have comparable clinical and histopathological features, both being granulomatous diseases frequently affecting the lungs. A well known feature is the increased risk of reactivating a latent TB infection or worsening of an active TB infection caused by immunosuppressive TNF- $\alpha$  inhibitors [89]. Therefore, screening for TB is recommended before starting anti-TNF- $\alpha$ . However, no evidence is available on the screening methods for TB in patients on MTX. One retrospective study concluded that MTX treatment was probably not associated with an increased incidence of TB in rheumatic diseases [90]. Recommendations in RA stated that screening should therefore be similar to that in the general population [91]. However, some case reports showed the occurrence of active TB in patients on long-term MTX treatment [92]. Furthermore, the American College of Rheumatology (ACR) recommended that MTX should not be initiated in the presence of active TB or latent TB infection prior to starting preventive therapy [87]. Combining the available evidence, we recommend excluding mycobacterial infection in selected sarcoidosis cases using an IGRA test such as QuantiFERON-TB Gold In-Tube (QFT-GIT) assay or T-SPOT.TB assay, which seem to be accurate methods given the presence of anergy to tuberculin in sarcoidosis, prior to initiating further immunosuppressive treatment with MTX [93,94<sup>■</sup>].

The evidence available for RA was combined with the expert opinion amongst sarcoidologists and processed into recommendation 4. Contraindications that should be considered before the start of MTX in sarcoidosis are discussed in more detail at recommendation 5.

#### Recommendation 5

*Before starting MTX, some contraindications should be considered: significant renal disease, significant hepatic disease other than sarcoidosis, bone marrow depression and acute or chronic infection.*

There is no evidence regarding any contraindications that should be considered before the start of MTX in sarcoidosis. Contraindications that should be considered according to rheumatology experts include significant renal disease with

glomerular filtration rate (GFR) less than 30 ml/min, hepatic disorders, leucocytopenia less than  $3.0 \times 10^9/l$ , thrombocytopenia less than  $50 \times 10^9/l$ , inadequate contraception, pregnancy, history of drug or alcohol abuse, acute or chronic infection and pulmonary disease [87]. Renal and hepatic diseases, leucocytopenia, thrombocytopenia and infections were considered contraindications by 70–96% of the sarcoidologists in our survey, whereas pulmonary disease, anaemia and a history of alcohol/drugs use were less often mentioned (20–52%) (Table 2). In addition, GFR less than 30 ml/min was considered a contraindication by 54%, white blood cell (WBC) count of less than  $2.0 \times 10^9/l$  by 73%, platelet count of less than  $100 \times 10^9/l$  by 64% and haemoglobin (Hb) level of less than 5–6 mmol/l by 84% (Table 2). In general, sarcoidologists seem to take a more cautious approach than the rheumatology guidelines.

MTX is considered contraindicated by significant renal disease, as MTX is mainly cleared by the kidney [95]. Kidney involvement from sarcoidosis is rare, having been reported in 7–22% of sarcoidosis patients at autopsy, but sometimes leads to kidney failure [96]. Furthermore, renal failure can also be the consequence of hypercalcaemia and hypercalciuria, which are both frequent manifestations of sarcoidosis [96]. In these cases, AZA is recommended as the first-choice glucocorticosteroids-sparing immunomodulator (based on expert opinion).

Involvement of the liver often occurs in sarcoidosis, with liver biopsy demonstrating granulomatous disease in half of the patients [97<sup>■</sup>,98<sup>■</sup>,99–101]. Liver test abnormalities are seen in one-fourth to one half of sarcoidosis patients before the start of MTX; these can be the result of sarcoidosis or other liver diseases [47,97<sup>■</sup>]. Treatment with MTX is not contraindicated when liver test abnormalities are the consequence of sarcoidosis involvement [98<sup>■</sup>]. Treatment of inflammatory sarcoidosis activity can actually lead to improvement of liver tests [98<sup>■</sup>]. A study of baseline liver test abnormalities in rheumatology patients found that values were only mildly elevated and were rarely a contraindication for starting MTX [86<sup>■</sup>]. Liver test abnormalities at baseline are more common in sarcoidosis, because of liver disease from the sarcoidosis itself [47,97<sup>■</sup>]. In patients with severe liver test abnormalities prior to starting MTX, one should consider a liver biopsy or radiological examination to distinguish between sarcoidosis and other liver diseases [97<sup>■</sup>]. Acute and chronic hepatitis B and C infections are considered to represent contraindications [87].

Rheumatology guidelines consider pulmonary diseases, especially interstitial lung diseases of

unknown cause, to represent contraindications [87], as preexisting lung disease may be a risk factor for the development of MTX-induced pneumonitis [79]. In sarcoidosis, however, the main reasons for MTX prescription are pulmonary disease and respiratory functional impairment, which can be successfully treated with MTX. The presence of pulmonary disease in sarcoidosis as such is therefore not considered a contraindication to treatment with MTX, which is also reflected in the very low percentage of sarcoidologists (20%) considering pulmonary disease a contraindication (Table 2). Figure 1 shows an example of substantial improvement of parenchymal pulmonary lesions from sarcoidosis after treatment with MTX [102]. In cases of suspected or confirmed other pulmonary disease, such as acute or chronic infections, however, MTX should be considered contraindicated (based on expert opinion).

## Recommendation 6


*When starting MTX or increasing the dose, ALT with or without AST, creatinine and CBC should be monitored every 3–6 weeks until a stable dose is reached, and every 1–3 months thereafter; after stabilization the monitoring interval can be extended to every 6 months.*

No studies evaluating the frequency of monitoring have been done for sarcoidosis, and the recommended frequency of monitoring in RA is largely based on expert opinion [87]. The limited available evidence suggests an optimal interval to detect liver test abnormalities of 30–60 days and a decreasing incidence of MTX-induced liver damage in the first months of therapy [64<sup>■</sup>]. A total of 60% of the sarcoidosis experts suggested a monitoring interval of 2–6 weeks, whereas 95% suggested an interval of 1–3 months after a stable dosage has been reached (Table 2).

AST and ALT have been reported to correlate with the histological grades of liver disease in RA [64<sup>■</sup>,103–107]. Creatinine should also be monitored, as renal dysfunction is associated with increased risk of pulmonary toxicity. A CBC is required to monitor bone marrow toxicity [64<sup>■</sup>,78]. A baseline WBC count at the time of starting or increasing the dosage of MTX may be helpful to determine the follow-up interval for CBC: if baseline WBC count is low, a follow-up CBC should be performed at shorter intervals than with higher WBC count at baseline.

The 2008 ACR guidelines suggest monitoring every 1–3 months, with more frequent assessments initially [87]. As evidence regarding monitoring frequency in sarcoidosis is lacking, we have





**FIGURE 1.** High-resolution computed tomography (HRCT) studies from a 36-year-old man with a history of 5 years of biopsy-proven sarcoidosis. Because of respiratory functional impairment, he had been previously treated with prednisone, starting at 40 mg daily. This was tapered off because of side-effects to 20 mg daily. No improvement was achieved, so treatment with methotrexate (MTX) was started. (a) HRCT before treatment with MTX, showing multiple intraparenchymal nodules, focal pleural thickening, septal and nonseptal lines, and thickening or irregularity of the bronchovascular bundle [102]. (b) HRCT after 6 months of treatment with 12.5 mg MTX weekly and 5 mg folic acid once a week orally, together with 10 mg prednisone daily, showing substantial improvement.

combined the recommendations extrapolated from RA with expert opinion to recommend a monitoring frequency of 3–6 weeks until a stable dose is reached and every 1–3 months thereafter. After stabilization, the monitoring interval can be extended to 6 months. Despite the observations that MTX hepatotoxicity is rarer in RA than in sarcoidosis, which can probably be explained by the underlying liver disease from the sarcoidosis itself [28,83,84,101,107,108], we recommend a similar frequency pattern of liver testing in sarcoidosis. Severe liver disease as a result of MTX in sarcoidosis is rare [101].

### Recommendation 7

*In case of MTX-induced gastrointestinal side-effects, including mucositis, splitting the oral dose should be considered, provided the total MTX dose is ingested within a 12-h period. Parenteral administration or an alternative immunosuppressive drug should be considered in case of persistent intolerance.*

No studies are available comparing different administration modes in sarcoidosis. Recommendations for RA patients indicate a preference for the oral route when starting MTX treatment [64<sup>22</sup>,109]. The bioavailability of MTX at higher oral doses (25–35 mg weekly) is decreased in RA patients, most probably because of limited absorption from the gastrointestinal tract, and can be improved by splitting the oral dose [110,111]. No studies are available investigating the effectiveness of splitting the oral dose in terms of reducing the gastrointestinal side-effects. Almost half of the sarcoidosis experts in our survey, however, reported using splitting of the oral dose with ingestion of the total dose within a 12-h period as an alternative administration option in case of MTX-induced gastrointestinal side-effects (Table 2); they reported regularly observing the disappearance of inconvenient symptoms. The recommendation to ingest the total MTX dose within a 12-h period is based on the 5–8-h elimination half-life of MTX [95].

Retrospective studies in RA suggest higher efficacy and less gastrointestinal toxicity with parenteral versus oral administration of MTX, which can be explained by a higher bioavailability of the parenteral form [112–114]. The efficacy and safety of routes of administration were evaluated in open-label studies, which found a significant reduction in disease activity scores following the switch from oral to parenteral administration [109,115,116]. This leads to a recommendation for RA patients to switch to subcutaneous or intramuscular administration in case of gastrointestinal side-effects, poor compliance or inadequate effectiveness [109]. The variable bioavailability of high oral MTX dosages forms another argument to consider changing to parenteral administration [114]. Almost half of the sarcoidologists in our survey reported prescribing parenteral MTX as an alternative administration route in case of MTX-induced gastrointestinal side-effects (Table 2).

As evidence regarding the best administration routes of MTX in sarcoidosis is lacking, evidence extrapolated from RA, combined with expert opinion, resulted in the recommendation to split the oral dose, changing to parenteral administration routes or considering an alternative immunosuppressive drug in case of gastrointestinal intolerance.

**Recommendation 8**

*Caution is warranted if there is a confirmed increase in ALT/AST. If there are no other causes, it should lead to either MTX dose reduction or withdrawal, liver biopsy to evaluate for MTX toxicity or additional folic acid supplementation; consider an alternative immunosuppressive drug after normalization.*

Sarcoidosis commonly affects the liver [97<sup>■</sup>,99–101] and liver test abnormalities during MTX use may thus be due to the underlying sarcoidosis, but also due MTX use or some other cause [101]. Studies amongst RA patients have found a relatively low rate of MTX hepatotoxicity, with a reported 3–5% incidence of advanced pathological changes on liver biopsy [83,84,107,108]. Studies found that only patients with persistently elevated transaminase levels or decreased albumin levels had a toxic reaction to MTX [103–107]. Therefore, RA guidelines rely on the use of serial liver function testing to identify patients with a toxic reaction to MTX [64<sup>■</sup>]. Studies amongst sarcoidosis patients found a 9% incidence rate of MTX-associated toxic effects established by liver biopsy after 1 year of MTX therapy and a 14% incidence rate after 2 years of therapy [28,101]. However, no sarcoidosis patients were reported to have severe liver disease as a result of MTX therapy [101]. The higher incidence of hepatotoxicity in sarcoidosis compared to RA may be because of the underlying liver disease from the sarcoidosis itself [28,101]. As half of the patients showed changes in their liver biopsy results that were attributed to sarcoidosis, the associated inflammatory and fibrotic changes may overlap with the changes seen in toxic reactions to MTX and could therefore have led to overestimation of MTX toxicity [101]. In sarcoidosis, the ALP level at the time of biopsy [28,101] and the number of times the AST was elevated in the year before the biopsy [101] correlated with the severity of the toxic effect of MTX. However, patients with hepatic sarcoidosis showed higher levels of various liver tests as well [28,101]. Therefore, the absolute liver test results or the number of abnormal tests are not clinically useful for predicting either liver sarcoid involvement or MTX hepatotoxicity [28,101]. Nevertheless, as serial liver testing is a noninvasive safe way to trace liver disease including MTX toxicity, it is recommended for sarcoidosis patients on MTX therapy. Baughman *et al.* [101] also claimed an important role for liver biopsy in screening for toxic reactions.

Studies investigating how to deal with the liver test abnormalities in sarcoidosis patients using MTX, or the level of liver test abnormalities at which MTX should be discontinued, have been scarce. Forty-six per cent of the sarcoidologists in our survey

reported discontinuing MTX when liver test results exceeded the level of 3 times the upper limit of normal (ULN), whereas the remaining experts reported that they discontinued MTX at liver test results more than 2 times the ULN or more than 4 times the ULN (Table 2). Studies in RA recommended MTX withdrawal if there is a confirmed increase in ALT/AST of more than 2 times the ULN [64<sup>■</sup>]. The majority of sarcoidologists reported discontinuing or decreasing the dosage of MTX when liver test results exceed the level of 4 times the ULN, after checking for other causes of liver test abnormalities, such as alcohol or nonsteroidal anti-inflammatory drugs use (Table 2). Checking for other causes is important, as, for example, RA patients on MTX treatment who are heavy drinkers are more likely to show advanced changes on liver biopsy [108]. Rheumatology experts emphasize that other causal factors, including nonsteroidal anti-inflammatory drugs, obesity with nonalcoholic steatohepatitis and alcohol, should be considered in case of persistently elevated liver tests after discontinuation of MTX [64<sup>■</sup>]. Only 10% of the sarcoidosis experts reported that they first increased the dosage of folic acid to decrease the hepatotoxic effects of MTX (Table 2). However, no literature is available on the value of raising the folic acid dosage when liver test abnormalities increase during MTX use. Expert opinion, however, suggests some beneficial effects. Furthermore, the sarcoidologists did not agree with the recommendation by rheumatology experts to reinstitute MTX at a lower dose following normalization of liver tests [64<sup>■</sup>], but suggested considering an alternative immunosuppressive drug after normalization.

As there is no definite evidence regarding how to deal with an increase in liver test abnormalities during MTX treatment of sarcoidosis patients, we combined recommendations extrapolated from RA with sarcoidosis expert opinion to formulate recommendation 8.

**Recommendation 9**

*Based on its acceptable safety profile, MTX is appropriate for long-term use.*

There have been no studies with long-term follow-up data to conclusively determine the long-term safety profile of MTX for sarcoidosis patients. Adverse effects because of MTX are listed in appendix 1, <http://links.lww.com/COPM/A4>. As described above, gastrointestinal and liver toxicity were most frequently reported by the sarcoidologists as the reason to discontinue MTX, which was necessary in 10% of cases. However, Baughman *et al.* and Vucinic reported lower discontinuation rates of 0–4% [23<sup>■</sup>,24]. Sixty-eight per cent of the



experienced sarcoidologists reported continuing MTX unaltered in the long term (Table 2). Compared with AZA, MTX has comparable side-effects in sarcoidosis patients, except for a higher infection rate during AZA use [22<sup>11</sup>]. Leflunomide has been proposed to have a more favourable safety profile compared with MTX [117,118], but studies directly comparing MTX and leflunomide are lacking.

A large 6-year study found that RA patients on MTX had a lower mortality rate and reduced cardiovascular mortality [64<sup>12</sup>,119]. Furthermore, discontinuation of MTX because of toxicity in RA patients is unusual [120] and MTX is less frequently discontinued than other disease-modifying anti-rheumatic drugs [64<sup>12</sup>,121]. Long-term MTX use by RA patients was not associated with an increased risk of serious infections [64<sup>12</sup>,122]. Whether MTX in RA patients is associated with a low risk of developing lymphoma has not been fully elucidated [64<sup>12</sup>,123,124].

Despite the limited available evidence, the overall safety profile of MTX in the short term seems to be acceptable. As studies to determine the long-term safety profile of MTX in sarcoidosis patients are lacking, we surmise that the safety profile will be reasonably similar to that found for RA patients.

### Recommendation 10

*MTX should not be used by men or women for at least 3 months before planned pregnancy, and should not be used during pregnancy or breast feeding (absolute contraindication).*

No studies are available assessing the outcome of continued MTX therapy before or during pregnancy in sarcoidosis patients. A total of 99% of the experts in our survey asked female patients whether they had a pregnancy wish, and 71% did so with male patients. A total of 99% discontinued MTX if female patients wanted to become pregnant and 70% did the same for male patients (Table 2).

Six studies amongst RA patients assessed the outcome of continued MTX therapy before or during pregnancy ( $n=101$ ): they reported 24% miscarriages and 6% congenital malformations [64<sup>12</sup>,125–130], whereas lower percentages of miscarriages and congenital malformations were found in healthy women not using MTX [131]. No studies amongst RA patients have evaluated the effect of MTX use by men on pregnancy or fertility. Nevertheless, the recommendation for both male and female RA patients is to discontinue MTX at least 3 months before planned pregnancy [64<sup>12</sup>]. For sarcoidosis patients, similar incompatibility of MTX with planned or actual pregnancy and breast feeding is indisputable, so MTX should be discontinued by both men and women at least 3 months

before planned pregnancy, and should not be used during pregnancy or breast feeding.

## CONCLUSION

Ten multinational WASOG recommendations for the practical use of MTX in sarcoidosis were developed by integrating evidence from both a systematic literature search and the expert opinions of sarcoidologists worldwide, and were shown by an evaluation study to be supported by all leading sarcoidosis experts.

This is the first study addressing evidence-based recommendations for the optimized use of MTX in sarcoidosis. A unique feature was the involvement of 113 sarcoidosis experts from all over the world in the development of the recommendations, which allowed approaches to frequently encountered issues on the use of MTX in sarcoidosis in daily practice to be collected. The broad range of participants, involving all the leading international sarcoidosis experts, should enhance the implementation of these recommendations in sarcoidosis practice worldwide.

Our systematic literature search showed that RCT evidence supporting the use of MTX in sarcoidosis was very limited. Most of the published data were derived from observational case series, some of them including a large number of patients but most including only a small sample. A Cochrane review on DMARDs in pulmonary sarcoidosis found no data on MTX available for meta-analysis [7]. Furthermore, no long-term follow-up data were available, which is actually crucial in determining the long-term benefits, given the recurring nature of sarcoidosis. For most aspects, little or no evidence was found specifically relating to sarcoidosis, which limits the strength of the proposed recommendations. On the other hand, evidence on these aspects in RA was available from several RCTs and high-quality cohort studies. We extrapolated evidence from these studies to help develop the recommendations for MTX in sarcoidosis, especially where data for sarcoidosis were lacking. As the clinical problems encountered in sarcoidosis show many similarities with those in RA, lessons learned from the use of MTX in RA are extremely valuable. Nevertheless, certain scenarios and clinical challenges are unique to sarcoidosis, and should be considered separate from the evidence gained amongst RA patients. It is especially in these cases, therefore, that the expert opinion of sarcoidologists from all over the world was important. Moreover, the world's leading sarcoidosis experts reported a high level of agreement with the proposed recommendations, which strengthens their value.

Optimization of treatment with MTX and other glucocorticosteroids-sparing immunomodulators in

sarcoidosis is important to avoid overprescription of more expensive treatment modalities, such as TNF- $\alpha$  inhibitors. Optimized utilization of less expensive, but effective treatment modalities is important to keep the healthcare system affordable. MTX has proved to be the cornerstone of therapy in many immune-mediated diseases [15,16], and a survey found that 80% of physicians reported MTX to be their preferred second-line treatment option for sarcoidosis [13<sup>11</sup>,14]. Therefore, the proposed evidence-based recommendations may serve to help optimize the prescription of MTX in clinical practice. We think these recommendations will be useful for both experienced and less experienced MTX prescribers.

As studies investigating the use of MTX in sarcoidosis have been scarce, there is a need for RCTs looking into the effect of MTX on various well defined outcome measures in sarcoidosis with a reasonable duration of follow-up. In addition, side-effects and safety must be well documented. When patients fail to respond to MTX or develop severe toxicity symptoms necessitating MTX withdrawal, alternative treatment options such as AZA [22<sup>12</sup>], leflunomide [118] or biologicals [10] should be considered. However, specific guidelines for these treatment modalities are currently lacking. Future research should focus on establishing useful recommendations in clinical practice for these therapeutics as well.

In conclusion, we developed multinational WASOG recommendations for the use of MTX amongst sarcoidosis patients in routine clinical practice, by combining a systematic literature search with expert opinion, with the aim of promoting both evidence-based and patient-based medicine.

## Acknowledgements

*The authors greatly appreciate the efforts of the sarcoidosis experts who participated in this study by completing the questionnaires.*

## Conflicts of interest

*This study was supported by an educational grant from the ild care foundation and TEVA Nederland.*

## REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 584).

1. Hunninghake GW, Costabel U, Ando M, *et al.* ATS/ERS/WASOG Statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149–173.

2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305:391–399.
3. Baughman RP, Teirstein AS, Judson MA, *et al.* Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885–1889.
4. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; 2:CD001114.
5. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28:627–636.
6. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med 2008; 102:1–9.
7. Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006; 3:CD003536.
8. Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31:501–518.
9. Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and ■ experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41:1424–1438.

This review provides an extensive overview of support for older and new pharmacological treatment options in pulmonary sarcoidosis. The experimental treatment options such as inhaled vasoactive intestinal peptide (VIP), rituximab and ustekinumab with available evidence in sarcoidosis are presented.

10. Baughman RP, Drent M, Kavuru M, *et al.* Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795–802.
11. Judson MA, Baughman RP, Costabel U, *et al.* Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31:1189–1196.
12. Liu Y, Wu EQ, Bensimon AG, *et al.* Cost per responder associated with ■ biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012; 29:620–634.

This meta-analysis provides detailed information about the cost-effectiveness of biological therapies for different inflammatory diseases.

13. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based ■ recommendations. Expert Rev Clin Immunol 2012; 8:95–103.

Of all the available studies, this review provides the most detailed evidence-based stepwise approach for the treatment of sarcoidosis patients with different disease stages, which is useful in clinical practice.

14. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104:717–723.
15. Suarez-Almazor ME, Belseck E, Shea B, *et al.* Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; 2:CD000957.
16. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012; 8:CD003643.
17. Chan ES, Cronstein BN. Methotrexate – how does it really work? Nat Rev Rheumatol 2010; 6:175–178.
18. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic ■ obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131:636–645.

This article provides understanding of the anti-inflammatory effects of corticosteroids by a detailed description of the molecular mechanisms leading to steroid resistance.

This is important, as insight in these mechanisms can lead to more effective anti-inflammatory treatment.

19. Oxford Centre for Evidence-Based Medicine. Levels of evidence (March 2009). <http://www.cebm.net/index.aspx?o=1025>.
20. Roddy E, Zhang W, Doherty M, *et al.* Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 2006; 12:347–352.
21. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in ■ acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60–66.

This study is the only available randomized placebo-controlled trial of high quality ( $n=24$ ), showing the steroid-sparing potency of MTX in sarcoidosis.

22. Vorseleers AD, Wuyts WA, Vorseleers VM, *et al.* Methotrexate ■ versus azathioprine in second line therapy of sarcoidosis. Chest 2013; doi:10.1378/chest.12-1728. [Epub ahead of print]

A large international retrospective cohort study ( $n=200$ ) demonstrating the similar efficacy of AZA and MTX in sarcoidosis. This is till now the only available study comparing MTX with another DMARD in sarcoidosis.

23. Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular ■ sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:26–33.

A recent retrospective study examining the effect of MTX amongst a large population of patients with ocular sarcoidosis ( $n=365$ ), showing great effectiveness of MTX.

24. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8:470–476.
25. Zeitlin JF, Tami TA, Baughman R, Winget D. Nasal and sinus manifestations of sarcoidosis. Am J Rhinol 2000; 14:157–161.
26. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999; 106:111–118.
27. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864–1868.

28. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. *Arch Intern Med* 1995; 155:846–851.
  29. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. *Am Rev Respir Dis* 1990; 142:1268–1271.
  30. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. *Am J Med Sci* 1990; 299:153–157.
  31. Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. *Br J Dermatol* 1977; 97:213–216.
  32. Sakellariou GT, Anastasilakis AD, Karanikolas D, *et al*. Central skeletal sarcoidosis: a case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity. *Mod Rheumatol* 2013; 23:175–181.
  33. Alemdaroglu E, Erturk A, Eroglu AG. A sarcoidosis patient with hand involvement and large pulmonary lymph nodes: results of 1-year treatment with methotrexate. *Clin Rheumatol* 2013; 32 (Suppl.):S71–S73.
  34. Bouaziz A, Le Scannff J, Chapelon-Abric C, *et al*. Oral involvement in sarcoidosis: report of 12 cases. *QJM* 2012; 105:755–767.
  35. Delmonte L, Zamo A, Cantini M, de Franceschi L. An unusual case of sarcoidosis in an adult patient with sickle cell disease: management with methotrexate and low dose of steroid. *Am J Hematol* 2012; 88:243.
  36. Sakushima K, Yabe I, Nakano F, *et al*. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. *J Neurol* 2011; 258:2163–2167.
  37. Bargagli E, Olivieri C, Penza F, *et al*. Rare localizations of bone sarcoidosis: two case reports and review of the literature. *Rheumatol Int* 2011; 31:1503–1506.
  38. Gautam M, Patil S, Munde P. Skin as a marker of internal disease: a case of sarcoidosis. *Indian J Dermatol* 2011; 56:439–441.
  39. Lambert L, Riemer EC, Judson MA. Rapid development of sarcoid tenosynovitis. *J Clin Rheumatol* 2011; 17:201–203.
  40. Kimball MM, Wind JJ, Codispoti KE, *et al*. Neurosarcoidosis presenting as an isolated intrasellar mass: case report and review of the literature. *Clin Neuropathol* 2010; 29:156–162.
  41. Kalajian AH, Van Meter JR, Callen JP. Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil. *Arch Dermatol* 2009; 145:905–909.
  42. Mannam P, Boselli JM, Schulman ES. Successful treatment of chylous ascites secondary to sarcoidosis with methotrexate. *Hosp Pract* 2009; 37:144–146.
  43. Varron L, Broussolle C, Candessanche JP, *et al*. Spinal cord sarcoidosis: report of seven cases. *Eur J Neurol* 2009; 16:289–296.
  44. Suarez Zambrano GA, Hutton GJ. Heart-shaped lesion secondary to neurosarcoidosis. *Arch Neurol* 2008; 65:1388–1389.
  45. Morgan SS, Aslam MB, Mukkanna KS, Ampat G. A rare presentation of sarcoidosis, back pain and spondylolisthesis. *J Bone Joint Surg Br* 2008; 90:240–242.
  46. Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2006; 23:58–65.
  47. Kennedy PT, Zakaria N, Modawi SB, *et al*. Natural history of hepatic sarcoidosis and its response to treatment. *Eur J Gastroenterol Hepatol* 2006; 18:721–726.
  48. Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. *Clin Exp Dermatol* 2005; 30:120–124.
  49. Gardner GC, Hunter JC. Clinical images: radiographic healing of osseous sarcoidosis. *Arthritis Rheum* 2005; 52:2225.
  50. Braun JJ, Gentile A, Pauli G. Sinusoidal sarcoidosis: review and report of fifteen cases. *Laryngoscope* 2004; 114:1960–1963.
  51. Maust HA, Foroosan R, Sergott RC, *et al*. Use of methotrexate in sarcoid-associated optic neuropathy. *Ophthalmology* 2003; 110:559–563.
  52. Moin M, Kersten RC, Bernardini F, Kulwin DR. Destructive eyelid lesions in sarcoidosis. *Ophthalm Plast Reconstr Surg* 2001; 17:123–125.
  53. Scola RH, Werneck LC, Prevedello DM, *et al*. Symptomatic muscle involvement in neurosarcoidosis: a clinicopathological study of 5 cases. *Arq Neuropsiquiatr* 2001; 59:347–352.
  54. Diri E, Espinoza CG, Espinoza LR. Spinal cord granulomatous vasculitis: an unusual clinical presentation of sarcoidosis. *J Rheumatol* 1999; 26:1408–1410.
  55. Mana J, Gomez-Vaquero C, Dorca J, Pujol R. Vertebral and rib sarcoidosis: long-term clinical remission with methotrexate. *Clin Rheumatol* 1999; 18:492–494.
  56. Gedalia A, Molina JF, Ellis GS Jr, *et al*. Low-dose methotrexate therapy for childhood sarcoidosis. *J Pediatr* 1997; 130:25–29.
  57. Kaye O, Palazzo E, Grossin M, *et al*. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. *Br J Rheumatol* 1995; 34:642–644.
  58. Henderson CA, Ilchysyn A, Curry AR. Laryngeal and cutaneous sarcoidosis treated with methotrexate. *J R Soc Med* 1994; 87:632–633.
  59. Suda T, Sato A, Toyoshima M, *et al*. Weekly low-dose methotrexate therapy for sarcoidosis. *Intern Med* 1994; 33:437–440.
  60. Webster GF, Razzi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. *J Am Acad Dermatol* 1991; 24:451–454.
  61. Soriano FG, Caramelli P, Nitri R, Rocha AS. Neurosarcoidosis: therapeutic success with methotrexate. *Postgrad Med J* 1990; 66:142–143.
  62. Webster GF, Razzi LK, Sanchez M, Shupack JR. Methotrexate therapy in cutaneous sarcoidosis. *Ann Intern Med* 1989; 111:538–539.
  63. Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. *Ann Intern Med* 1968; 69:1247–1248.
  64. Visser K, Katchamart W, Loza E, *et al*. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis* 2009; 68:1086–1093.
- Evidence-based recommendations for the use of MTX in rheumatic disorders integrating a systematic literature review and expert opinion of an international panel of rheumatologists, addressing all important issues of MTX use in rheumatic diseases.
65. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. *Lancet Neurol* 2004; 3:397–407.
  66. Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2001; 18:133–137.
  67. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. *JAMA* 1978; 240:2654–2655.
  68. Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. *Sarcoidosis* 1988; 5:51–55.
  69. Furst DE, Koehnke R, Burmeister LF, *et al*. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. *J Rheumatol* 1989; 16:313–320.
  70. Schnabel A, Reinhold-Keller E, Willmann V, Gross WL. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. *Rheumatol Int* 1994; 14:33–38.
  71. Verstappen SM, Jacobs JW, van der Veen MJ, *et al*. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007; 66:1443–1449.
  72. Shea B, Swinden MV, Tanjong Ghogomu E, *et al*. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev* 2013; 5:CD000951.
  73. Van Ede AE, Laan RF, Rood MJ, *et al*. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2001; 44:1515–1524.
  74. Morgan SL, Baggott JE, Vaughn WH, *et al*. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. *Ann Intern Med* 1994; 121:833–841.
  75. Morgan SL, Baggott JE, Vaughn WH, *et al*. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 1990; 33:9–18.
  76. Griffith SM, Fisher J, Clarke S, *et al*. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? *Rheumatology (Oxford)* 2000; 39:1102–1109.
  77. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. *Br J Dermatol* 2009; 160:622–628.
  78. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. *Rheumatoid Arthritis Clinical Trial Archive Group*. *J Rheumatol* 1995; 22:218–223.
  79. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. *J Rheumatol* 1995; 22:1043–1047.
  80. Cottin V, Tebib J, Massonnet B, *et al*. Pulmonary function in patients receiving long-term low-dose methotrexate. *Chest* 1996; 109:933–938.
  81. Beyeler C, Jordi B, Gerber NJ, Im Hof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. *Br J Rheumatol* 1996; 35:446–452.
  82. Hagiyaama H, Kubota T, Komano Y, *et al*. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. *Clin Exp Rheumatol* 2004; 22:375–376.
  83. Shergy WJ, Polisson RP, Caldwell DS, *et al*. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. *Am J Med* 1988; 85:771–774.
  84. Phillips CA, Cera PJ, Mangan TF, Newman ED. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. *J Rheumatol* 1992; 19:229–233.
  85. Minocha A, Dean HA, Pittsley RA. Liver cirrhosis in rheumatoid arthritis patients treated with long-term methotrexate. *Vet Hum Toxicol* 1993; 35:45–48.
  86. Le Boedec M, Marhadour T, Devauchelle-Pensec V, *et al*. Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VerA, and Brittany). *Semin Arthritis Rheum* 2013; 42:474–481.
- An overview of the recommendations about preadministration laboratory work-up in different countries. Evaluation of laboratory abnormalities according to these recommendations in patients with early arthritis showed a prevalence of only 2% contraindicating MTX therapy.



87. Saag KG, Teng GG, Patkar NM, *et al.* American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 2008; 59:762–784.
  88. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. *Arthritis Rheum* 1996; 39:723–731.
  89. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2012; 51 (Suppl. 5):v38–v47.
  90. Vellido Font C, Hernandez-Garcia C, Pato E, *et al.* Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases. *Rev Clin Esp* 2003; 203:178–182.
  91. Bogas M, Machado P, Mourao AF, *et al.* Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. *Clin Rheumatol* 2010; 29:629–635.
  92. Maejima H, Watarai A, Nakano T, *et al.* Adverse effects of methotrexate in three psoriatic arthritis patients. *Rheumatol Int* 2012; doi:10.1007/s00296-012-2649-0. [Epub ahead of print]
  93. Gupta D, Kumar S, Aggarwal AN, *et al.* Interferon gamma release assay (Quantiferon-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. *Sarcoidosis Vasc Diffuse Lung Dis* 2011; 28:95–101.
  94. Redelman-Sidi G, Sepkowitz KA. Interferon gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. *Am J Respir Crit Care Med* 2013; doi:10.1164/rccm.201209-1621Cl. [Epub ahead of print]
- A detailed overview of disease circumstances in which an IGRA test as screening method for latent TB infection is recommended.
95. Bannwarth B, Pehourcq F, Schaeferbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. *Clin Pharmacokinet* 1996; 30:194–210.
  96. Holmes J, Lazarus A. Sarcoidosis: extrathoracic manifestations. *Dis Mon* 2009; 55:675–692.
  97. Cremers J, Drent M, Driessen A, *et al.* Liver-test abnormalities in sarcoidosis. *Eur J Gastroenterol Hepatol* 2012; 24:17–24.
- The first study demonstrating that severity of liver test abnormalities was significantly related with the degree of fibrosis and extensiveness of the granulomatous inflammation in sarcoidosis.
98. Cremers JP, Drent M, Baughman RP, *et al.* Therapeutic approach of hepatic sarcoidosis. *Curr Opin Pulm Med* 2012; 18:472–482.
- Current opinion with regard to pharmacological approach of patients with hepatic sarcoidosis, providing a stepwise approach.
99. Hercules HD, Bethlem NM. Value of liver biopsy in sarcoidosis. *Arch Pathol Lab Med* 1984; 108:831–834.
  100. Devaney K, Goodman ZD, Epstein MS, *et al.* Hepatic sarcoidosis. Clinicopathologic features in 100 patients. *Am J Surg Pathol* 1993; 17:1272–1280.
  101. Baughman RP, Koehler A, Bejarano PA, *et al.* Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. *Arch Intern Med* 2003; 163:615–620.
  102. Drent M, De Vries J, Lenters M, *et al.* Sarcoidosis: assessment of disease severity using HRCT. *Eur Radiol* 2003; 13:2462–2471.
  103. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. *Arthritis Rheum* 1989; 32:121–127.
  104. Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. *J Rheumatol* 1996; 23:459–461.
  105. Tolman KG, Clegg DO, Lee RG, Ward JR. Methotrexate and the liver. *J Rheumatol Suppl* 1985; 12 (Suppl. 12):29–34.
  106. Willkens RF, Leonard PA, Clegg DO, *et al.* Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis. *Ann Rheum Dis* 1990; 49:591–593.
  107. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. *Arthritis Rheum* 1986; 29:822–831.
  108. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. *Am J Med* 1991; 90:711–716.
  109. Pavy S, Constantin A, Pham T, *et al.* Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. *Joint Bone Spine* 2006; 73:388–395.
  110. Hoekstra M, Haagsma C, Neef C, *et al.* Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. *J Rheumatol* 2006; 33:481–485.
  111. Van Roon EN, van de Laar MA. Methotrexate bioavailability. *Clin Exp Rheumatol* 2010; 28:S27–S32.
  112. Rozin A, Schapira D, Balbir-Gurman A, *et al.* Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. *Ann Rheum Dis* 2002; 61:756–757.
  113. Jundt JW, Browne BA, Fiocco GP, *et al.* A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. *J Rheumatol* 1993; 20:1845–1849.
  114. Hoekstra M, Haagsma C, Neef C, *et al.* Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. *J Rheumatol* 2004; 31:645–648.
  115. Lambert CM, Sandhu S, Lochhead A, *et al.* Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. *Arthritis Rheum* 2004; 50:364–371.
  116. Bingham SJ, Buch MH, Lindsay S, *et al.* Parenteral methotrexate should be given before biological therapy. *Rheumatology (Oxford)* 2003; 42:1009–1010.
  117. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2004; 21:43–48.
  118. Sahoo DH, Bandyopadhyay D, Xu M, *et al.* Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. *Eur Respir J* 2011; 38:1145–1150.
  119. Choi HK, Hernan MA, Seeger JD, *et al.* Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 2002; 359:1173–1177.
  120. Yazici Y, Sokka T, Kautiainen H, *et al.* Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. *Ann Rheum Dis* 2005; 64:207–211.
  121. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis* 2009; 68:1100–1104.
  122. Doran MF, Crowson CS, Pond GR, *et al.* Predictors of infection in rheumatoid arthritis. *Arthritis Rheum* 2002; 46:2294–2300.
  123. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and antitumor necrosis factor therapy in 18,572 patients. *Arthritis Rheum* 2004; 50:1740–1751.
  124. Mariette X, Cazals-Hatem D, Warszawski J, *et al.* Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. *Blood* 2002; 99:3909–3915.
  125. Ostensen M, von Eisebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. *J Rheumatol* 2007; 34:1266–1269.
  126. Ostensen M, Hartmann H, Salvessen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. *J Rheumatol* 2000; 27:1872–1875.
  127. Lewden B, Vial T, Elefant E, *et al.* Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. *J Rheumatol* 2004; 31:2360–2365.
  128. Kozlowski RD, Steinbrunner JV, MacKenzie AH, *et al.* Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. *Am J Med* 1990; 88:589–592.
  129. Donnenfeld AE, Pastuszak A, Noah JS, *et al.* Methotrexate exposure prior to and during pregnancy. *Teratology* 1994; 49:79–81.
  130. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of child-bearing age: a survey of practice patterns and pregnancy outcomes. *J Rheumatol* 2003; 30:241–246.
  131. Regan L, Rai R. Epidemiology and the medical causes of miscarriage. *Baillieres Best Pract Res Clin Obstet Gynaecol* 2000; 14:839–854.